Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...

Q3 2024 Earnings Call Transcript November 18, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the NRx ...

"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...

Dermatologists and experts advise consumers to carefully check labels and be wary of many products on the market, especially those on social media, that may contain harmful substances.

Weight-loss drugs promise to make the pounds melt away, and beauty products and fillers will erase those fine lines. But do you know what you're getting or where it's coming from?

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

BridgeBio (BBIO) Pharma presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Navi Mumbai-based Intergraphic Sales and Services sold two Pulisi kits, the DSmart 330 F digital press and the PAIM370S ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...